Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 -0.00226757369614508
Stock impact report

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Revolution Medicines, Inc. (RVMD) 
Company Research Source: GlobeNewswire
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first mutant-selective RAS(ON) Inhibitor to enter clinic, following closely behind company’s RASMULTI(ON) Inhibitor, RMC-6236 REDWOOD CITY, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation. RMC-6291, which exhibits a potential best-in-class preclinical profile, is the first drug candidate from the company’s pipeline of mutant-selective RAS(ON) Inhibitors to enter the clinic. Last quarter, Revolution Medicines initiated clinical development of RMC-6236, its oral RASMULTI(ON) Inhibit Show less Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RVMD alerts

from News Quantified
Opt-in for
RVMD alerts

from News Quantified